Aravive Inc (ARAV) Stock
ARAV is no longer traded. Aravive was delisted from the Nasdaq in January 2024.
Prices on this page are historical; the last trade was January 26, 2024 at $0.04.
Aravive stock price history
ARAV final trading statistics
- Final close
- $0.04
- Final trading day
- Jan 26, 2024
- Market cap at delisting
- $2.95M
- Shares outstanding
- 73.56M
- Final 52-week range
- $0.04 – $2.46
- Avg. volume (final 3 mo.)
- 2,427,311
- All-time high (split-adj.)
- $204.00 · Jun 2014
- All-time low (split-adj.)
- $0.04 · Jan 2024
- Return since IPO
- -100.0%
- Beta
- 2.19
- Book value / share
- $0.02
- Price / book
- 1.74
Aravive annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $6.99M | -$39.8M | — |
| FY2022 | $9.14M | -$80.9M | -$2.20 |
| FY2021 | $7.44M | -$38.1M | -$1.94 |
| FY2020 | $5.68M | -$34.2M | -$1.95 |
| FY2019 | $4.75M | -$20.3M | -$1.58 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Aravive Inc
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
Aravive stock FAQ
What happened to Aravive stock?
Aravive stock was delisted from the Nasdaq. Its final close was $0.04 on January 26, 2024.
Is ARAV stock still trading?
No. ARAV was delisted from the Nasdaq in January 2024 and no longer trades on a U.S. exchange.
What was the last price of ARAV stock?
ARAV closed at $0.04 on its final trading day, January 26, 2024, for a market value of about $2.95M.
What were Aravive's revenue and earnings in its last full fiscal year?
Aravive reported revenue of $6.99M and net income of -$39.8M in fiscal 2023, its last full year as a public company.
When did Aravive go public?
Aravive Inc stock began trading on March 21, 2014.